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CURRENT OPINION Open Access
Inspiration for the Future: The Role of
Inspiratory Muscle Training in Cystic
Fibrosis
Ren-Jay Shei1,2* , Robert L. Dekerlegand3 , Kelly A. Mackintosh4 , John D. Lowman2,5 and Melitta A. McNarry4
Abstract
Cystic fibrosis (CF) is an inherited, multi-system, life-limiting disease characterized by a progressive decline in lung
function, which accounts for the majority of CF-related morbidity and mortality. Inspiratory muscle training (IMT)
has been proposed as a rehabilitative strategy to treat respiratory impairments associated with CF. However, despite
evidence of therapeutic benefits in healthy and other clinical populations, the routine application of IMT in CF can
neither be supported nor refuted due to the paucity of methodologically rigorous research. Specifically, the
interpretation of available studies regarding the efficacy of IMT in CF is hampered by methodological threats to
internal and external validity. As such, it is important to highlight the inherent risk of bias that differences in patient
characteristics, IMT protocols, and outcome measurements present when synthesizing this literature prior to making
final clinical judgments. Future studies are required to identify the characteristics of individuals who may respond to
IMT and determine whether the controlled application of IMT can elicit meaningful improvements in physiological
and patient-centered clinical outcomes. Given the equivocal evidence regarding its efficacy, IMT should be utilized
on a case-by-case basis with sound clinical reasoning, rather than simply dismissed, until a rigorous evidence-based
consensus has been reached.
Key Points
 Preliminary evidence indicates that inspiratory
muscle training could enhance respiratory muscle
function in CF, although whether this translates to
meaningful physiological and patient-centered
improvements is unclear.
 The poor quality of evidence limits the conclusions
that can be drawn and highlights the need for future
studies that utilize appropriate measures and
training protocols and characterize the patient
population to enable conclusions to be drawn
regarding the potential therapeutic benefits of IMT
in CF.
 Until such studies have been conducted, conclusions
on the value of IMT as a treatment tool in CF
cannot be drawn and as such, IMT should be
considered on a case-by-case basis.
Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic
disorder caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene that
results in multi-organ pathologies involving the respira-
tory, digestive, and reproductive systems [1–3]. Specific
to the respiratory system, aberrant or absent CFTR
channels produce a dehydrated, hyper-viscous, and
acidic mucosal layer that promotes an airway environ-
ment prone to chronic infection and inflammation that
leads to progressive lung injury. Airway obstruction
becomes evident in pulmonary function tests as does a
progressive lung hyperinflation associated with a reduc-
tion in forced expiratory volume in 1 s (FEV1) [4, 5].
The resultant increased work of breathing (WOB) and
decreased gas exchange contribute to impaired exercise
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capacity and ultimately respiratory failure, which is the
leading cause of CF-related mortality [1, 2].
Alterations in pulmonary mechanics associated with
progressive CF pathophysiology include the adoption of
a rapid, shallow breathing pattern [6], which may delay
respiratory muscle fatigue [7], but also contribute to
increased WOB and impaired gas exchange [6, 8].
Multiple CF-related comorbidities, including thoracic
kyphosis and postural abnormalities, can create a re-
strictive lung dysfunction that elevates the demand im-
posed on the respiratory pump [9, 10]. Thus, individuals
with CF commonly exhibit an imbalance between the
ventilatory load and the capacity of the respiratory mus-
cles, which is exemplified by the adoption of inefficient
breathing patterns [6] and exercise intolerance [11].
Although alterations in pulmonary mechanics and
WOB in individuals with CF are clear, it is equivocal
whether individuals with CF exhibit respiratory (inspira-
tory and/or expiratory) muscle dysfunction or preserved
respiratory muscle function [12, 13]. It is evident, how-
ever, that respiratory muscle function is influenced by a
variety of factors including hyperinflation, nutritional
status [14], systemic corticosteroid use, Pseudomonas
aeruginosa colonization, inactivity, and chronic inflam-
mation [15]. Importantly, respiratory muscle perform-
ance in CF is a key determinant of aerobic fitness [15],
which is closely associated with survival [16] and quality
of life (QoL) [17–19]. Thus, addressing whether inspira-
tory and expiratory muscle function is preserved or
aberrant in CF will be important to identify novel
methods to optimize respiratory pump function in CF,
including inspiratory muscle training (IMT).
Strategies to enhance respiratory muscle function in
the presence of a load/capacity imbalance and to coun-
teract the disease-related decline in pulmonary function
have been suggested, with one potential strategy being
IMT [20, 21]. While specific loading protocols vary,
IMT typically utilizes either a pressure or volume load
on the inspiratory muscles to provide a stimulus to elicit
a training response [22], similar to that observed in re-
sponse to training peripheral musculature. Indeed, IMT
has been shown to be an effective ergogenic aid to en-
hance exercise performance in healthy adults [23–26]
and has been investigated as a therapeutic intervention
to improve clinical and functional outcomes in a variety
of health conditions including asthma, chronic obstruct-
ive pulmonary disease (COPD), heart failure, and stroke
[27–33]. However, the applicability of IMT as a thera-
peutic strategy in those with CF remains equivocal [20].
Nonetheless, whilst recent reviews have provided a com-
prehensive summary of the current evidence base, little
attention has been given to the methodological limita-
tions associated with this evidence, which largely
confounds its interpretation and should temper any
conclusions. Therefore, the purpose of the present
opinion paper is to draw attention to past and ongoing
challenges with IMT studies and to provide recommen-
dations on how future studies may seek to address such
shortcomings to provide a better understanding of how
IMT may, or may not, fit into the armamentarium of
tools to manage CF.
Current State of IMT in CF
A summary of peer-reviewed publications on IMT in
individuals with CF is given in Table 1. Despite the re-
habilitative and therapeutic potential of IMT, its clinical
efficacy and long-term application in CF remains incon-
clusive as no study to date has provided strong evidence
of significant improvements in clinical outcomes, regard-
less of improvements in inspiratory muscle performance.
It should be noted, however, that IMT has been associ-
ated with improved exercise tolerance [34] and improved
health-related QoL within the mastery and emotion
domains [34, 35]. The apparent limited utility of IMT to
translate to clinically meaningful outcomes must be
interpreted in the context of multiple methodological
limitations and the obvious paucity of available studies.
Indeed, the most recent Cochrane review only identified
nine reports eligible for inclusion [20]. Whilst the overall
conclusion of this review appears to be appropriate
based on the available evidence, several parameters that
may underpin the equivocal findings were not
adequately discussed, such as the methods utilized to
quantify respiratory muscle function [36]. Furthermore,
little distinction was made between children and adults
within this recent review, despite significant physiologic
and psychosocial age-related differences that may impact
the plasticity and response to IMT. This observation is
of particular concern given the inherent interaction be-
tween age and disease progression in CF, which is highly
likely to influence the efficacy of any intervention. The
lack of available data limits child-adult comparisons, and
although Hilton et al. [20] proposed an arbitrary 16-
year-old cut-point to distinguish adults, this threshold
may be inappropriate given the delayed biological matur-
ation that may occur with CF [37, 38].
The conflicting and uncertain results on the efficacy of
IMT in CF may also be partially explained by variations
in training protocols between studies [21]. Indeed, the
contention that flow-based and threshold modes of IMT
provide a similar training stimulus to the muscles, as
cited in the recent Cochrane review [20], is controver-
sial. Specifically, threshold devices do not provide a
constant challenge throughout the inspiratory effort,
while flow-based training is dependent on flow rates and
breathing pattern [39]. In accord with skeletal muscle
adaptations to training, it is vital to identify the optimal
training protocol prior to conclusions being drawn
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regarding the efficacy of any training stimulus. At least
in healthy humans, the efficacy of IMT as an ergogenic
aid appears to be optimal when the IMT loading proto-
col is closely matched to the ventilatory demands of the
criterion task (i.e., exercise modality) [24, 25], which has
not been identified in CF. Indeed, the optimization of
IMT is likely to be a highly individualized process re-
quiring the IMT protocol to be matched with specifically
identified respiratory muscle impairments. In this man-
ner, an appropriate IMT protocol targeting strength
and/or endurance deficits based on the individual’s
needs may elicit optimal physiological benefits. However,
despite their potential impact on intervention efficacy,
these considerations have not been rigorously controlled
for in prior studies on IMT in CF.
Further to resolving these methodological issues, the
potential mechanisms underpinning the ability of IMT
to elicit meaningful physiological and psychosocial bene-
fits should be considered. It is possible that the apparent
variability in the effect of IMT reflects inter-participant
variations in disease manifestation and management that
are of significant clinical and functional relevance,
Table 1 Summary matrix of original published studies investigating inspiratory muscle training in individuals with cystic fibrosis
Study Patient
demographics*
Protocol Comparison Primary outcomes
Asher,
1982
Age: 16.0 ± 4.6
%BMI: 82.6 ± 9.9
%FEV1: 35.0 ±
12.3
MIP: 74 ± 18
Mode: Flow-based
Intensity: Rmax
Frequency: BID
Duration: 15 min/day; 4 weeks
Subjects served as their own
controls with a 4-week control
period followed by a 4-week
intervention period.
Increase in IMS (9.5%; p < 0.025) and IME;
no effect on exercise performance.
Sawyer,
1993
Age: 11.5 ± 2.5
BMI**: 18.4
NIHS: 87.7
MIP: 107 ± 29
Mode: Threshold
Intensity: 50–60% MIP
Frequency: 7 days/week
Duration: 30 min/day; 10 weeks
Compared to a sham group
who performed trained at
≤ 10% MIP.
Increase in MIP (13%; p < 0.01), VC (17%),
TLC (13%; p < 0.01), and maximal exercise
capacity (9.8%; p < 0.03) with observed
increase in sputum production.
De Jong,
2001
Age: 17 ± 5.2
BMI**: 17.9
%FEV1: 70 ± 25
%MIP: 105 ± 23
Mode: Threshold
Intensity: 40% MIP
Frequency: 5 days/week
Duration: 20 min; 6 weeks
Compared to a sham group
who performed trained at
10% MIP.
Increase in IME (35%; p = 0.003) with no
significant effect on exercise, dyspnea,
or fatigue.
Enright,
2004
Age: 24.8 ± 5.5
BMI**: 22.3
%FEV1: 64.2 ±
29.7
MIP: 134 ± 26
Mode: Computer interface
Intensity: 80% SMIP
Frequency: 3 days/week
Duration: 6 sets, 6 reps; 8 weeks
Compared to a sham group
at 20% SMIP and a control group.
Increased SMIP and MIP with 80% and
20% training groups with no between
group differences. Increased diaphragmatic
thickness (20%), VC (24%), TLC (12%), and
PWC (51%); decreased anxiety and depression
in the 80% group only.
Santana-
Sosa, 2014
Age: 11 ± 1
BMI: 16.6 ± 0.7
FEV1: 1.65 ± 0.19
MIP: 68.3 ± 6.3
Mode: Threshold combined with
exercise program.
Intensity: 40–50% MIP
Frequency: BID
Duration: ~ 5 min of 30
inspirations; 8 weeks
Compared to a sham group
who was trained at 10% MIP.
Increased MIP (58%), VO2peak (22%), and
muscular strength in the intervention group.
Bieli, 2017 Sequence IC***
Age: 15.4 (12.0:
16.6)
BMI**: 17.8
zFEV1: − 0.9 (−
2.8:0.5)
MIP: Not
reported
Sequence CI***
Age: 13.2 (10.9:
17.8)
BMI**: 19.7
zFEV1: − 2.1 (−
3.4 : - 0.5)
MIP: Not
reported
Mode: Eucapnic hyperventilation
Intensity: Not reported
Frequency: BID, 5 days/week
Duration: 10 min; 8 weeks
Randomized crossover
comparison.
Increased RME (105%) but not exercise
endurance, lung function, or quality of life.
BID two times per day, BMI body mass index, %BMI body mass index percentile, %FEV1 percent of predicted forced expiratory volume in 1 s, FEV1 forced
expiratory volume in 1 s expressed as liters per second, zFEV1 forced expiratory volume in 1 s expressed a z-score, %RV percent of predicted residual volume, Rmax
greatest resistance sustainable for 10min, IMS inspiratory muscle strength, IME inspiratory muscle endurance, %MIP percent of predicted maximal inspiratory
pressure, MIP maximal inspiratory pressure in cmH2O, NIHS National Institutes of Health Score for disease severity, NR not reported, QD daily, PWC physical work
capacity, SMIP sustained maximal inspiratory pressure, TLC total lung capacity, VC vital capacity, VO2 peak peak rate of oxygen consumption
*Patient demographics given for baseline characteristics of the intervention group
**Calculated from height and weight provided in the article
***Values presented as median (interquartile range); CI control—intervention sequence, IC intervention—control sequence
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especially as the drive towards personalized/precision
medicine continues [40, 41].
Inspiratory Muscle Training: Potential Mechanistic Basis
for Adaptations
The specific mechanisms by which IMT can transfer to
meaningful outcomes in individuals with CF are unclear
and likely multifactorial. However, several putative
mechanisms have emerged, including (i) hypertrophy of
the diaphragm and external intercostal muscles, (ii) an
increase in the proportion of type I fibers in the external
intercostal muscles, (iii) improvement in respiratory
muscle economy and efficiency, (iv) reduction in the
work of breathing, (v) enhanced respiratory muscle
strength and endurance, (vi) attenuation of the respira-
tory muscle metaboreflex, (vii) reduction in cytokine
release, (viii) reorganization of respiratory muscle motor
recruitment pattern, (ix) decreased inspiratory muscle
motor drive with preserved inspiratory pressure gener-
ation, and (x) decreased rating of perceived breathless-
ness and/or rating of perceived exertion [24, 42]. These
mechanisms are likely interrelated and not mutually
exclusive. Their interaction, and ultimately their impact
on exercise performance, is not well understood. Whilst
these potential mechanisms have been identified in
healthy populations and their applicability to clinical
populations, such as CF, remains to be elucidated, there
are no grounds to postulate that the mechanisms may
differ, although the emphasis on each factor may be dis-
ease-specific. For example, a reduction in cytokine
release may be especially beneficial in a disease charac-
terized by systemic inflammation, further highlighting
the potential utility of IMT if shown to be effective.
Expert Opinion on IMT in CF
Although IMT has the potential to be a useful rehabilita-
tive and therapeutic tool for the management of CF lung
disease, several crucial weaknesses in the current body
of literature must be addressed in order to clarify its de-
gree of utility. The grading of the evidence for IMT in
CF as “very low quality” in the most recent Cochrane
systematic review [20] highlights the challenges of con-
ducting IMT studies in those with CF. The heterogeneity
between and within studies, including wide variations in
methodologies and outcome measures, the incomplete
reporting of important parameters such as clinical
status, and in the methods of randomization, allocation,
and blinding [20], preclude firm conclusions to support
or refute the use of IMT in this population. Indeed,
methodologically rigorous studies that accurately and
completely report these factors are required to come to
a valid, evidence-based, consensus regarding the thera-
peutic efficacy of IMT in individuals with CF. The
primary challenges within studies of IMT in those with
CF that need to be addressed include (i) adequate
consideration and controlling of the characteristics of
the patient population, (ii) carefully targeting the IMT
protocol based on individual needs, and (iii) selecting
outcome measures that best capture both physiological
adaptations and patient-centered clinical outcomes.
Careful consideration of the patient population will be
required, with future studies encouraged to control for
contextual factors including, but not limited to, age, dis-
ease severity, baseline respiratory muscle performance,
bacterial colonization status, modulator therapy status,
aerobic fitness, body composition, rate of pulmonary
function deterioration, and mutation class. Figure 1 pre-
sents the International Classification of Functioning,
Disability, and Health framework on components ultim-
ately affecting QoL in CF. Research is needed to identify
which of these components are most influential in
mediating and/or moderating the response to IMT, and
controlling for these components should be a priority in
future studies. Specific to IMT, in addition to respiratory
muscle function or dysfunction (including both inspira-
tory and expiratory muscles), core stability and pelvic
floor function may also impact the response to IMT. At
present, there is a dearth of published data describing
whether these factors are abnormal in CF; nevertheless,
these factors may still influence respiratory muscle
performance and should therefore be accounted for in
future studies of IMT in CF. Additionally, IMT may also
improve both core stability and pelvic floor function sug-
gesting these may be important outcome factors to in-
clude in future studies as well. In the meantime, the use of
strict inclusion and exclusion eligibility criteria will ensure
a more homogeneous sample population and thereby
address at least some of these components. In addition,
the development of a standardized method of assessing,
and subsequently grading, disease status and severity
according to phenotypic determinants of respiratory
muscle impairments would facilitate a more targeted,
personalized approach to IMT, acknowledging that IMT
may not benefit all with CF to the same degree.
Identifying the most suitable IMT protocol presents
another significant challenge for IMT studies, with fur-
ther research warranted to distinguish the most salient
merits associated with the different types of resistive
loading, including pressure-threshold and flow-resistive
loading, as well as volume loading (i.e., voluntary hyper-
pnea) [27]. Importantly, the optimal training volume and
intensity for IMT protocols must be elucidated; we must
seek to move away from the reliance on a “one-size-fits-
all” approach. Indeed, due to the phenotypic heterogen-
eity in those with CF, innovative IMT programs that
provide a sufficient training dose to elicit specific
physiological adaptations in the respiratory muscles need
to be developed. For example, a patient who exhibits
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significant respiratory muscle weakness but preserved
respiratory muscle endurance should receive a markedly
different training protocol compared to a patient with
preserved respiratory muscle strength but diminished
respiratory muscle endurance. Furthermore, it is likely
that some of those with CF, particularly those who
experience a pseudo-training effect as a result of chronic
airway obstruction, may require a higher training work-
load compared with healthier counterparts. Indeed,
analogous findings have been reported in healthy elite
swimmers in whom the habitual exposure to an in-
creased WOB, due to the hydrostatic pressure the water
exerts on the thorax, ameliorates the potential benefits
typically engendered by IMT [44], an effect not found
with lower exposures to this increased WOB [45, 46].
Alternatively, some individuals with CF may simply not
benefit from IMT. For example, it is possible that par-
ticularly in the presence of mild disease and preserved
respiratory muscle function, IMT may not be of any
additional benefit to the current standard of care. The
ergogenic effect of strength training on limb locomotor
muscles appears to be optimized when athletes perform
strength training to task failure [47–49]. Therefore, the
development of CF-specific IMT protocols that progress
to task failure (e.g., failure to generate a given inspiratory
pressure during IMT) may provide the greatest potential
therapeutic benefit of IMT in those with CF [50]. IMT
performed at 100% of PImax has been shown to decrease
exercising heart rate and perceived exertion, whereas
IMT performed at 80% of PImax did not produce any
such adaptations [51]. Presently, the test of incremental
respiratory endurance (TIRE) regimen, which consists of
a series of training breaths with a decreasing work-rest
ratio, may be the best example of such an IMT protocol
[22, 24, 27, 52–54]. Specifically, this type of training pre-
scription may be better suited to inducing respiratory
Fig. 1 The International Classification of Functioning, Disability and Health (ICF) framework describing the interrelated body structure/function
impairments, activity limitations, and participation restrictions that can occur in cystic fibrosis, limitations, and restrictions as a result of CF, and
highlights (in bold) those that, in particular, are related to inspiratory muscle function. Adapted from [43]
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muscle adaptations in those with CF compared with pro-
tocols simply requiring a fixed number of breaths in
each training session. Similarly, adopting a “high-inten-
sity interval training” (HIIT)-like prescription of IMT
may also enhance the potential efficacy and sustainability
of this training modality, as HIIT has been shown to be
effective in inducing similar training adaptations to those
observed following whole-body exercise training in a
more time-efficient manner.
Most IMT studies report pulmonary function-related
outcome measures such as FEV1 and FVC, as well as
some respiratory muscle performance parameters such
as maximal inspiratory and expiratory mouth pressures
(PImax and PEmax, respectively), to gauge respiratory
muscle strength. However, these measures alone may
not be sufficient to evaluate the efficacy of IMT on en-
hancing respiratory muscle performance [52]. Employing
additional outcome measures to detect physiological ad-
aptations, such as diaphragm and external intercostal
muscle hypertrophy and motor unit recruitment pattern
changes, will be informative as to whether IMT is effect-
ive in inducing true training adaptations. However, it is
important to be cognizant that many such measures are
not in routine clinical use and are therefore likely to be
unfamiliar to people with CF and their interdisciplin-
ary care teams. Consequently, these data may not be
useful for many practitioners as they are unable to draw
meaningful conclusions. Thus, these additional measures
should be considered in conjunction with functional and
clinical measures, such as respiratory muscle economy,
ventilatory efficiency, breathing patterns, dyspnea, QoL,
and participant burden.
Finally, and of utmost importance, is not whether IMT
can improve respiratory muscle performance per se, but
whether these improvements can transfer to more
meaningful, patient-centered clinical outcomes such as
those from maximal cardiopulmonary exercise testing
(e.g., aerobic capacity, peak ventilation, ventilatory
threshold, ventilatory efficiency) [55], health-related
QoL, morbidity, health-care utilization, and even mortal-
ity. This interdisciplinary, holistic approach will allow
for a more complete understanding of the physiological
adaptations and subsequent clinical outcomes that can
result from IMT in those with CF. This is particularly
important given that those with CF already face a high
burden of care [56]. Therefore, identifying whether IMT
provides additive or unique benefits distinct from exer-
cise training alone will aid in establishing whether IMT
has value in the standard of care for individuals with CF.
Conclusion
The potential for IMT to be a useful therapeutic tool in
CF care remains equivocal. The present lack of quality
empirical evidence supporting or refuting the use of
IMT in CF highlights the challenges of designing and
conducting IMT studies in CF. Future research should
seek to address these challenges. Specifically, more thor-
ough and complete reporting of important demographic
information, including considerations of pertinent clin-
ical outcome data, as well as an assessment of targeted
training effects of IMT should provide a more compre-
hensive understanding of its efficacy in those with CF.
Similarly, developing a standardized method for asses-
sing and quantifying respiratory muscle (dys) function in
order to individualize IMT training programs in CF is of
utmost importance. Finally, future research should
consider whether the potential benefits of IMT outweigh
the additional burden placed in those living with CF.
Abbreviations
CF: Cystic fibrosis; CFTR: Cystic fibrosis transmembrane conductance
regulator; COPD: Chronic obstructive pulmonary disease; FEV1: Forced
expiratory volume in 1 second; IMT: Inspiratory muscle training;
PEmax: Maximal expiratory mouth pressure; PImax: Maximal inspiratory mouth
pressure; QoL: Quality of life; TIRE: Test of incremental respiratory endurance;
WOB: Work of breathing
Acknowledgements
None.
Authors’ Contributions
RS, RD, KM, JL, and MM all contributed to the manuscript conception,
preparation, and final editing. All authors approved the final manuscript
before submission.
Funding
This work was supported by the National Institutes of Health/National Heart,
Lung, and Blood Institute [Ren-Jay Shei: T32HL105346] and the Cystic Fibrosis
Foundation [John D. Lowman: CCPT250-16]. The funders had no role in the
design, interpretation, or writing of the manuscript.
Availability of Data and Materials
Data sharing is not applicable to this article as no datasets were generated
or analyzed during the current study.
Ethics Approval and Consent to Participate
Not applicable.
Consent for Publication
Not applicable
Competing Interests
The authors, Ren-Jay Shei, Robert L. Dekerleg, Kelly A. Mackintosh, John D.
Lowman, and Melitta A. McNarry, declare that they have no competing
interests.
Author details
1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of
Medicine, University of Alabama at Birmingham, 1918 University Boulevard,
Birmingham, AL 35294-0006, USA. 2Gregory Fleming James Cystic Fibrosis
Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.
3Department of Physical Therapy, College of Rehabilitation Sciences,
Jefferson (Philadelphia University and Thomas Jefferson University),
Philadelphia, PA, USA. 4Applied Sports Science Technology and Medicine
Research Centre (A-STEM), College of Engineering, Swansea University,
Swansea, UK. 5Department of Physical Therapy, School of Health Professions,
University of Alabama at Birmingham, Birmingham, AL, USA.
Shei et al. Sports Medicine - Open            (2019) 5:36 Page 6 of 8
Received: 28 March 2019 Accepted: 31 July 2019
References
1. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat
Rev Dis Primers. 2015;1:15010. https://doi.org/10.1038/nrdp.2015.10.
2. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519-2531. doi:https://doi.
org/https://doi.org/10.1016/S0140-6736(16)00576-6.
3. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Eng J Med. 2005;352(19):
1992–2001. https://doi.org/10.1056/NEJMra043184.
4. Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir
Med. 2013;1(2):148-157. doi:https://doi.org/https://doi.org/10.1016/S2213-26
00(13)70026-2.
5. Kraemer R, Aebi C, Casaulta Aebischer C, Gallati S. Early detection of lung
disease and its association with the nutritional status, genetic background
and life events in patients with cystic fibrosis. Respiration. 2000;67(5):477–90.
6. Hart N, Polkey MI, Clément A, Boulé M, Moxham J, Lofaso F, et al. Changes
in pulmonary mechanics with increasing disease severity in children and
young adults with cystic fibrosis. Am J Respir Crit Care Med. 2002;166(1):61–
6. https://doi.org/10.1164/rccm.2112059.
7. Hahn A, Ankermann T, Claass A, Mann M, Lindemann H, Neubauer BA. Non-
invasive tension time index in relation to severity of disease in children with
cystic fibrosis. Pediatr Pulmonol. 2008;43(10):973–81. https://doi.org/10.1002/
ppul.20887.
8. Thin AG, Dodd JD, Gallagher CG, Fitzgerald MX, McLoughlin P. Effect of
respiratory rate on airway deadspace ventilation during exercise in cystic
fibrosis. Respir Med. 2004;98(11):1063-1070. doi:https://doi.org/https://doi.
org/10.1016/j.rmed.2004.03.016.
9. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe
kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern
Med. 1998;128(3):186–93. https://doi.org/10.7326/0003-4819-128-3-19980201
0-00004.
10. Denton JR, Tietjen R, Gaerlan PF. Thoracic kyphosis in cystic fibrosis. Clin
Orthop Relat Res. 1981;155:71–4.
11. Almajed A, Lands LC. The evolution of exercise capacity and its limiting
factors in cystic fibrosis. Paediatr Respir Rev. 2012;13(4):195–9. https://doi.
org/10.1016/j.prrv.2012.01.001.
12. Dekerlegand RL, Hadjiliadis D, Swisher AK, Parrott JS, Heuer AJ, Myslinski MJ.
Inspiratory muscle strength relative to disease severity in adults with stable
cystic fibrosis. J Cyst Fibros. 2015;14(5):639–45. https://doi.org/10.1016/j.jcf.2
015.05.003.
13. Heinzmann-Filho JP, Marostica PJ, Donadio MV. Ventilatory muscle strength
in cystic fibrosis patients: a literature review. Monaldi Arch Chest Dis =
Archivio Monaldi per le malattie del torace. 2012;77(3-4):134–8. https://doi.
org/10.4081/monaldi.2012.147.
14. Dekerlegand RL, Hadjiliadis D, Swisher AK, Parrott JS, Heuer AJ, Myslinski MJ.
Clinical predictors of inspiratory muscle strength in adults with stable cystic
fibrosis: a pilot study. Cardiopulm Phys Ther J. 2017;28(4):136–46. https://doi.
org/10.1097/cpt.0000000000000064.
15. Dassios T. Determinants of respiratory pump function in patients with cystic
fibrosis. Paediatr Respir Rev. 2015;16(1):75-79. doi:https://doi.org/https://doi.
org/10.1016/j.prrv.2014.01.001.
16. Vendrusculo FM, Heinzmann-Filho JP, da Silva JS, Perez Ruiz M, Donadio
MVF. Peak oxygen uptake and mortality in cystic fibrosis: systematic review
and meta-analysis. Respir Care. 2018.
17. Hebestreit H, Schmid K, Kieser S, Junge S, Ballmann M, Roth K, et al. Quality
of life is associated with physical activity and fitness in cystic fibrosis. BMC
Pulm Med. 2014;14(1):26. https://doi.org/10.1186/1471-2466-14-26.
18. Albinni S, Rath R, Renner S, Eichler I. Additional inspiratory muscle training
intensifies the beneficial effects of cycle ergometer training in patients with
cystic fibrosis. J Cyst Fibros. 2004;3(11S):S63.
19. Moorcroft AJ, Dodd ME, Morris J, Webb AK. Symptoms, lactate and exercise
limitation at peak cycle ergometry in adults with cystic fibrosis. Eur Resp J.
2005;25(6):1050–6. https://doi.org/10.1183/09031936.05.00011404.
20. Hilton N, Solis-Moya A. Respiratory muscle training for cystic fibrosis.
Cochrane Database Syst Rev. 2018;5:CD006112. https://doi.org/10.1
002/14651858.CD006112.pub4.
21. Reid WD, Geddes EL, O'Brien K, Brooks D, Crowe J. Effects of inspiratory
muscle training in cystic fibrosis: a systematic review. Clin Rehabil. 2008;
22(10-11):1003–13. https://doi.org/10.1177/0269215508090619.
22. Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ. Inspiratory muscle
training improves lung function and exercise capacity in adults with cystic
fibrosis. Chest. 126(2):405–11. https://doi.org/10.1378/chest.126.2.405.
23. Karsten M, Ribeiro GS, Esquivel MS, Matte DL. The effects of inspiratory
muscle training with linear workload devices on the sports performance
and cardiopulmonary function of athletes: a systematic review and meta-
analysis. Phys Ther Sport. 2018;34:92-104. doi:https://doi.org/https://doi.org/1
0.1016/j.ptsp.2018.09.004.
24. Shei R-J. Recent advancements in our understanding of the ergogenic
effect of respiratory muscle training in healthy humans: a systematic review.
J Strength Cond Res. 2018;32(9):2665–76. https://doi.org/10.1519/jsc.
0000000000002730.
25. HajGhanbari B, Yamabayashi C, Buna TR, Coelho JD, Freedman KD, Morton
TA, et al. Effects of respiratory muscle training on performance in athletes: a
systematic review with meta-analyses. J Strength Cond Res. 2013;27(6):
1643–63. https://doi.org/10.1519/JSC.0b013e318269f73f.
26. Illi SK, Held U, Frank I, Spengler CM. Effect of respiratory muscle training on
exercise performance in healthy individuals. Sports Med. 2012;42(8):707–24.
https://doi.org/10.1007/BF03262290.
27. Shei R-J, Paris HLR, Wilhite DP, Chapman RF, Mickleborough TD. The role of
inspiratory muscle training in the management of asthma and exercise-
induced bronchoconstriction. Phys Sportsmed. 2016;44(4):327–34. https://
doi.org/10.1080/00913847.2016.1176546.
28. Menezes KKP, Nascimento LR, Ada L, Polese JC, Avelino PR, Teixeira-Salmela
LF. Respiratory muscle training increases respiratory muscle strength and
reduces respiratory complications after stroke: a systematic review. J
Physiother. 2016;62(3):138-144. doi:https://doi.org/https://doi.org/10.1016/j.
jphys.2016.05.014.
29. Cahalin LP, Arena RA. Breathing exercises and inspiratory muscle training in
heart failure. Heart Failure Clin. 2015;11(1):149–72. https://doi.org/10.1016/j.
hfc.2014.09.002.
30. Smart NA, Giallauria F, Dieberg G. Efficacy of inspiratory muscle training in
chronic heart failure patients: a systematic review and meta-analysis. Int J
Cardiol. 2013;167(4):1502-1507. doi:https://doi.org/https://doi.org/10.1016/j.
ijcard.2012.04.029.
31. Charususin N, Gosselink R, Decramer M, Demeyer H, McConnell A, Saey D,
et al. Randomised controlled trial of adjunctive inspiratory muscle training
for patients with COPD. Thorax. 2018;73:942–50. https://doi.org/10.1136/
thoraxjnl-2017-211417.
32. Charususin N, Dacha S, Gosselink R, Decramer M, Von Leupoldt A, Reijnders
T, et al. Respiratory muscle function and exercise limitation in patients with
chronic obstructive pulmonary disease: a review. Expert Rev Respir Med.
2018;12(1):67–79. https://doi.org/10.1080/17476348.2018.1398084.
33. Gosselink R, De Vos J, van den Heuvel SP, Segers J, Decramer M, Kwakkel G.
Impact of inspiratory muscle training in patients with COPD: what is the evidence?
Eur Resp J. 2011;37(2):416–25. https://doi.org/10.1183/09031936.00031810.
34. Sawyer EH, Clanton TL. Improved pulmonary function and exercise
tolerance with inspiratory muscle conditioning in children with cystic
fibrosis. Chest. 104(5):1490–7. https://doi.org/10.1378/chest.104.5.1490.
35. Chatham K, Ionescu A, Davies S, Baldwin J, Enright S, Shale D. Through
range computer generated inspiratory muscle training in cystic fibrosis.
Pediatr Pulmonol. 1997;340:S299.
36. ATdN S, GAdF F, Ramsook AH, Guenette JA, INDF L, Reid WD. Respiratory
muscle endurance after training in athletes and non-athletes: a systematic
review and meta-analysis. Phys Ther Sport. 2016;17:76–86. https://doi.org/1
0.1016/j.ptsp.2015.08.001.
37. Aswani N, Taylor C, McGaw J, Pickering M, Rigby A. Pubertal growth and
development in cystic fibrosis: a retrospective review. Acta Paediatr. 2003;
92(9):1029–32. https://doi.org/10.1111/j.1651-2227.2003.tb02571.x.
38. Johannesson M, Gottlieb C, Hjelte L. Delayed puberty in girls with cystic
fibrosis despite good clinical status. Pediatrics. 1997;99(1):29–34. https://doi.
org/10.1542/peds.99.1.29.
39. McConnell AK, Weiner P, Romer LM. Inspiratory muscle training as a tool for
the management of patients with COPD. Eur Resp J. 2004;24(3):510–1.
https://doi.org/10.1183/09031936.04.00034904.
40. Marson FAL, Bertuzzo CS, Ribeiro JD. Personalized or precision medicine?
The example of cystic fibrosis. Front Pharmacol. 2017;8(390). https://doi.
org/10.3389/fphar.2017.00390.
41. Cholon DM, Gentzsch M. Recent progress in translational cystic fibrosis research
using precision medicine strategies. J Cyst Fibros. 2018;17(2 Supplement):S52-S60.
doi:https://doi.org/https://doi.org/10.1016/j.jcf.2017.09.005.
Shei et al. Sports Medicine - Open            (2019) 5:36 Page 7 of 8
42. Sheel AW, Boushel R, Dempsey JA. Competition for blood flow distribution
between respiratory and locomotor muscles: implications for muscle
fatigue. J Appl Physiol. 2018;125(3):820–31. https://doi.org/10.1152/
japplphysiol.00189.2018.
43. World Health Organization, 2001. International Classification of Functioning,
Disability, and Health (ICF), Geneva
44. Mickleborough T, Stager J, Chatham K, Lindley M, Ionescu A. Pulmonary
adaptations to swim and inspiratory muscle training. Eur J Appl Physiol.
2008;103(6):635–46. https://doi.org/10.1007/s00421-008-0759-x.
45. Shei R-J, Lindley MR, Chatham K, Mickleborough TD. Effect of flow-resistive
inspiratory loading on pulmonary and respiratory muscle function in sub-
elite swimmers. J Sports Med Phys Fitness. 2016;56(4):392–8.
46. Lomax M, Kapus J, Brown PI, Faghy M. Impact of weekly swimming training
distance on the ergogenicity of inspiratory muscle training in well trained
youth swimmers. J Strength Cond Res. 2019;33(8):2185–93.
47. Burd NA, West DWD, Staples AW, Atherton PJ, Baker JM, Moore DR, et al. Low-
load high volume resistance exercise stimulates muscle protein synthesis more
than high-load low volume resistance exercise in young men. PLoS One. 2010;
5(8):e12033. https://doi.org/10.1371/journal.pone.0012033.
48. Schoenfeld BJ, Peterson MD, Ogborn D, Contreras B, Sonmez GT. Effects of
low- vs. high-load resistance training on muscle strength and hypertrophy
in well-trained men. J Strength Cond Res. 2015;29(10):2954–63. https://doi.
org/10.1519/jsc.0000000000000958.
49. Schoenfeld BJ, Wilson JM, Lowery RP, Krieger JW. Muscular adaptations in
low- versus high-load resistance training: a meta-analysis. Eur J Sport Sci.
2016;16(1):1–10. https://doi.org/10.1080/17461391.2014.989922.
50. Shei R-J, Mickleborough TD. Unresolved questions that need to be
addressed in order to maximize the efficacy of inspiratory muscle training.
Phys Ther Sport. 2019;35:97-98. doi:https://doi.org/https://doi.org/10.1016/j.
ptsp.2018.11.009.
51. Gething AD, Passfield L, Davies B. The effects of different inspiratory muscle
training intensities on exercising heart rate and perceived exertion. Eur J
Appl Physiol. 2004;92(1-2):50–5. https://doi.org/10.1007/s00421-004-1044-2.
52. Cahalin LP, Arena R. Novel methods of inspiratory muscle training via the
test of incremental respiratory endurance (TIRE). Exerc Sport Sci Rev. 2015;
43(2):84–92. https://doi.org/10.1249/jes.0000000000000042.
53. Chatham K, Baldwin J, Griffiths H, Summers L, Enright S. Inspiratory muscle
training improves shuttle run performance in healthy subjects.
Physiotherapy. 1999;85(12):676-683. doi:http://dx.doi.org/https://doi.org/10.1
016/S0031-9406(05)61231-X.
54. Shei R-J, Chapman RF, Gruber AH, Mickleborough TD. Inspiratory muscle
training improves exercise capacity with thoracic load carriage. Physiol Rep.
2018;6(3):e13558. https://doi.org/10.14814/phy2.13558.
55. Hebestreit H, Arets HGM, Aurora P, Boas S, Cerny F, Hulzebos EHJ, et al.
Statement on exercise testing in cystic fibrosis. Respiration. 2015;90(4):332–51.
56. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with
cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;
8(2):91-96. doi:https://doi.org/https://doi.org/10.1016/j.jcf.2008.09.007.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Shei et al. Sports Medicine - Open            (2019) 5:36 Page 8 of 8
